S&P 500   4,287.20 (-0.29%)
DOW   33,491.05 (-0.52%)
QQQ   358.35 (+0.09%)
AAPL   171.27 (+0.34%)
MSFT   316.07 (+0.77%)
META   301.19 (-0.91%)
GOOGL   130.96 (-1.02%)
AMZN   127.36 (+1.10%)
TSLA   249.95 (+1.45%)
NVDA   435.62 (+1.10%)
NIO   9.01 (+1.12%)
BABA   86.76 (+1.43%)
AMD   103.60 (+0.82%)
T   15.01 (+0.00%)
F   12.40 (-1.27%)
MU   68.19 (+4.59%)
CGC   0.79 (-3.45%)
GE   110.53 (-1.61%)
DIS   80.91 (+0.97%)
AMC   7.98 (+2.44%)
PFE   33.11 (+3.18%)
PYPL   58.40 (+0.38%)
NFLX   377.03 (+0.18%)
S&P 500   4,287.20 (-0.29%)
DOW   33,491.05 (-0.52%)
QQQ   358.35 (+0.09%)
AAPL   171.27 (+0.34%)
MSFT   316.07 (+0.77%)
META   301.19 (-0.91%)
GOOGL   130.96 (-1.02%)
AMZN   127.36 (+1.10%)
TSLA   249.95 (+1.45%)
NVDA   435.62 (+1.10%)
NIO   9.01 (+1.12%)
BABA   86.76 (+1.43%)
AMD   103.60 (+0.82%)
T   15.01 (+0.00%)
F   12.40 (-1.27%)
MU   68.19 (+4.59%)
CGC   0.79 (-3.45%)
GE   110.53 (-1.61%)
DIS   80.91 (+0.97%)
AMC   7.98 (+2.44%)
PFE   33.11 (+3.18%)
PYPL   58.40 (+0.38%)
NFLX   377.03 (+0.18%)
S&P 500   4,287.20 (-0.29%)
DOW   33,491.05 (-0.52%)
QQQ   358.35 (+0.09%)
AAPL   171.27 (+0.34%)
MSFT   316.07 (+0.77%)
META   301.19 (-0.91%)
GOOGL   130.96 (-1.02%)
AMZN   127.36 (+1.10%)
TSLA   249.95 (+1.45%)
NVDA   435.62 (+1.10%)
NIO   9.01 (+1.12%)
BABA   86.76 (+1.43%)
AMD   103.60 (+0.82%)
T   15.01 (+0.00%)
F   12.40 (-1.27%)
MU   68.19 (+4.59%)
CGC   0.79 (-3.45%)
GE   110.53 (-1.61%)
DIS   80.91 (+0.97%)
AMC   7.98 (+2.44%)
PFE   33.11 (+3.18%)
PYPL   58.40 (+0.38%)
NFLX   377.03 (+0.18%)
S&P 500   4,287.20 (-0.29%)
DOW   33,491.05 (-0.52%)
QQQ   358.35 (+0.09%)
AAPL   171.27 (+0.34%)
MSFT   316.07 (+0.77%)
META   301.19 (-0.91%)
GOOGL   130.96 (-1.02%)
AMZN   127.36 (+1.10%)
TSLA   249.95 (+1.45%)
NVDA   435.62 (+1.10%)
NIO   9.01 (+1.12%)
BABA   86.76 (+1.43%)
AMD   103.60 (+0.82%)
T   15.01 (+0.00%)
F   12.40 (-1.27%)
MU   68.19 (+4.59%)
CGC   0.79 (-3.45%)
GE   110.53 (-1.61%)
DIS   80.91 (+0.97%)
AMC   7.98 (+2.44%)
PFE   33.11 (+3.18%)
PYPL   58.40 (+0.38%)
NFLX   377.03 (+0.18%)
NASDAQ:RLMD

Relmada Therapeutics (RLMD) News Today

$3.00
+0.06 (+2.04%)
(As of 03:26 PM ET)
Compare
Today's Range
$2.92
▼
$3.02
50-Day Range
$2.48
▼
$3.79
52-Week Range
$1.81
▼
$38.68
Volume
79,607 shs
Average Volume
216,201 shs
Market Capitalization
$90.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.80
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability
SourceHeadline
finance.yahoo.com logoHere's Why We're Watching Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Situation
finance.yahoo.com - September 26 at 7:13 AM
finance.yahoo.com logoRelmada (RLMD) Up on Positive Data for Anti-Depressant Candidate
finance.yahoo.com - September 21 at 5:37 PM
benzinga.com logoRelmada Therapeutics' Lead Candidate Shows Promise In Pivotal Depression Study
benzinga.com - September 20 at 1:52 PM
marketwatch.com logoRelmada Therapeutics Shares Rise 18% After Positive Trial Data for REL-1017
marketwatch.com - September 20 at 10:35 AM
markets.businessinsider.com logoRelmada Therapeutics: Long-term Study With REL-1017 Shows Rapid, Sustained Therapeutic Effects
markets.businessinsider.com - September 20 at 8:51 AM
finance.yahoo.com logoRelmada Therapeutics Announces Efficacy and Safety Results from the Phase 3 Long-Term Study of REL-1017 in Major Depressive Disorder
finance.yahoo.com - September 20 at 8:51 AM
msn.com logoRelmada Therapeutics: Run Up Likely Into Phase 3 Results, Enhanced By Possible Interim Readout
msn.com - September 1 at 9:03 PM
markets.businessinsider.com logoMizuho Securities Reaffirms Their Buy Rating on Relmada Therapeutics (RLMD)
markets.businessinsider.com - August 23 at 6:51 PM
finance.yahoo.com logoFollowing a 88% decline over last year, recent gains may please Relmada Therapeutics, Inc. (NASDAQ:RLMD) institutional owners
finance.yahoo.com - August 16 at 6:49 AM
markets.businessinsider.com logoRelmada Therapeutics (RLMD) Gets a Buy from Mizuho Securities
markets.businessinsider.com - August 9 at 4:33 PM
finanznachrichten.de logoRelmada Therapeutics, Inc.: Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
finanznachrichten.de - August 9 at 9:44 AM
fool.com logoRelmada Therapeutics (NASDAQ: RLMD)
fool.com - June 21 at 11:42 PM
finance.yahoo.com logoRelmada Therapeutics to Participate in the Goldman Sachs Global Healthcare Conference
finance.yahoo.com - June 8 at 10:24 AM
benzinga.com logoROSEN, RESPECTED INVESTOR COUNSEL, Encourages Relmada Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – RLMD
benzinga.com - June 3 at 2:10 PM
finance.yahoo.com logoRelmada Therapeutics to Participate in the 2023 Jefferies Global Healthcare Conference
finance.yahoo.com - June 2 at 8:56 AM
finance.yahoo.com logoRelmada Therapeutics Insider Ups Holding By 62% During Year
finance.yahoo.com - May 24 at 10:51 AM
finance.yahoo.com logoRelmada Therapeutics to Present Data at the American Society of Clinical Psychopharmacology 2023 Annual Meeting
finance.yahoo.com - May 24 at 8:13 AM
finance.yahoo.com logoRelmada Therapeutics Insider Ups Holding By 62% During Year \
finance.yahoo.com - May 24 at 8:13 AM
markets.businessinsider.com logoSVB Securities Reaffirms Their Buy Rating on Relmada Therapeutics (RLMD)
markets.businessinsider.com - May 15 at 4:25 PM
finanznachrichten.de logoRelmada Therapeutics, Inc.: Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
finanznachrichten.de - May 12 at 4:00 AM
markets.businessinsider.com logoMizuho Securities Sticks to Their Buy Rating for Relmada Therapeutics (RLMD)
markets.businessinsider.com - May 11 at 10:59 PM
msn.com logoRelmada Therapeutics: Q1 Earnings Insights
msn.com - May 11 at 8:35 PM
finance.yahoo.com logoRelmada Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
finance.yahoo.com - May 11 at 5:59 PM
benzinga.com logoEarnings Preview For Relmada Therapeutics
benzinga.com - May 10 at 3:16 PM
marketwatch.com logoRLMD NEWS: The Klein Law Firm Initiates an Investigation Involving Possible Securities Fraud Violations by Officers of Relmada Therapeutics, Inc.
marketwatch.com - May 9 at 11:03 PM
benzinga.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Relmada Therapeutics, Inc. - RLMD
benzinga.com - May 8 at 7:19 PM
marketwatch.com logoRLMD ALERT: The Law Offices of Vincent Wong Investigate Relmada Therapeutics, Inc. for Potential Violations of Securities Laws
marketwatch.com - May 8 at 12:00 PM
finance.yahoo.com logoRelmada Therapeutics to Report First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 11, 2023
finance.yahoo.com - May 8 at 8:57 AM
marketwatch.com logoRLMD FRAUD ALERT: Jakubowitz Law is Investigating Relmada Therapeutics, Inc. in Connection with Potential Violations of Federal Securities Laws
marketwatch.com - May 5 at 10:47 AM
msn.com logoUnusual Put Option Trade in Relmada Therapeutics (RLMD) Worth $75.00K
msn.com - May 4 at 9:35 PM
finance.yahoo.com logoWill Relmada Therapeutics (NASDAQ:RLMD) Spend Its Cash Wisely?
finance.yahoo.com - April 12 at 3:26 PM
markets.businessinsider.com logoSVB Securities Sticks to Their Buy Rating for Relmada Therapeutics (RLMD)
markets.businessinsider.com - March 28 at 7:35 AM
finance.yahoo.com logoQ4 2022 Relmada Therapeutics Inc Earnings Call
finance.yahoo.com - March 24 at 10:01 AM
finanznachrichten.de logoRelmada Therapeutics, Inc.: Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results
finanznachrichten.de - March 24 at 7:35 AM
finance.yahoo.com logoRelmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results
finance.yahoo.com - March 23 at 6:44 PM
benzinga.com logoPreview: Relmada Therapeutics's Earnings
benzinga.com - March 22 at 2:36 PM
finance.yahoo.com logoRelmada Therapeutics to Report Fourth Quarter and Full-Year 2022 Financial Results and Host Conference Call and Webcast on March 23, 2023
finance.yahoo.com - March 17 at 9:47 AM
finance.yahoo.com logoRelmada Therapeutics, Inc. (NASDAQ:RLMD) is favoured by institutional owners who hold 52% of the company
finance.yahoo.com - February 17 at 7:56 AM
marketbeat.com logoRelmada Therapeutics, Inc. (NASDAQ:RLMD) Given Average Recommendation of "Hold" by Brokerages
marketbeat.com - February 17 at 4:20 AM
nasdaq.com logoDeep Track Capital Now Owns 9.43% of Relmada Therapeutics (RLMD)
nasdaq.com - February 16 at 11:48 PM
marketbeat.com logoShort Interest in Relmada Therapeutics, Inc. (NASDAQ:RLMD) Decreases By 20.4%
marketbeat.com - February 13 at 4:42 AM
markets.businessinsider.com logoSVB Securities Keeps Their Buy Rating on Relmada Therapeutics (RLMD)
markets.businessinsider.com - January 23 at 9:56 AM
finance.yahoo.com logoRelmada Therapeutics Appoints CNS Therapeutic Expert Cedric O'Gorman MD as Chief Medical Officer
finance.yahoo.com - January 9 at 9:56 AM
finance.yahoo.com logoSergio Traversa Is The CEO & Director of Relmada Therapeutics, Inc. (NASDAQ:RLMD) And They Just Picked Up 62% More Shares
finance.yahoo.com - December 15 at 9:16 AM
marketbeat.com logoInsider Buying: Relmada Therapeutics, Inc. (NASDAQ:RLMD) CEO Buys 55,250 Shares of Stock
marketbeat.com - December 12 at 9:24 PM
msn.com logoLooking Into Relmada Therapeutics's Recent Short Interest
msn.com - December 9 at 12:50 PM
marketwatch.com logoRelmada Therapeutics Shares Plumb New Depths After Lead Program Setback >RLMD
marketwatch.com - December 8 at 3:26 PM
marketwatch.com logoRelmada Therapeutics Shares Slide Premarket on Study Failure >RLMD
marketwatch.com - December 8 at 10:26 AM
finance.yahoo.com logoRelmada Shares Nosedive As Another Depression Trial Goes Up In Smoke
finance.yahoo.com - December 8 at 10:26 AM
finance.yahoo.com logoRelmada Therapeutics shares decline 40% on Thursday
finance.yahoo.com - December 8 at 10:26 AM
Get Relmada Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for RLMD and its competitors with MarketBeat's FREE daily newsletter.



RLMD Media Mentions By Week

RLMD Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

RLMD
News Sentiment
▼
0.62

0.68
▲
Average
Medical
News Sentiment

RLMD News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

RLMD Articles
This Week
▼
2

1
▲
RLMD Articles
Average Week

Get Relmada Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for RLMD and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

Related Companies:
Headlines Tools:
This page (NASDAQ:RLMD) was last updated on 9/29/2023 by MarketBeat.com Staff

My Account -